Urologia Internationalis
Original Paper
Oxidative Stress in Benign Prostatic Hyperplasia and Prostate CancerPace G.a, b · Di Massimo C.a · De Amicis D.a · Corbacelli C.a · Di Renzo L.c · Vicentini C.a, b · Miano L.d · Tozzi Ciancarelli M.G.aaDepartment of Health Sciences, University of L’Aquila, L’Aquila, bUrology Unit, Mazzini Hospital, Teramo, cDepartment of Human Nutrition, University of Tor Vergata, Rome, and dDepartment of Urology, Sant’Andrea Hospital, University ‘La Sapienza’, Rome, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: November 26, 2009
Accepted: March 22, 2010
Published online: May 20, 2010
Issue release date: October 2010
Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 2
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Abstract
Objective: The aim was to verify whether oxidative stress could represent a common key factor of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Subjects and Methods: 15 patients affected by BPH, 15 with PCa and 15 controls were enrolled. Blood samples were withdrawn systemically and locally during radical retropubic prostatectomy in patients with PCa and during transvesical retropubic adenomectomy in patients diagnosed with BPH. Plasma oxidized low-density lipoprotein, peroxides, and total equivalent antioxidant capacity (TEAC) including plasma superoxide dismutase (SOD) determination were analyzed as oxidative markers. Results: With respect to the control group, high plasma peroxides and decreased TEAC levels were measured in patients affected by both PCa and BPH. Plasma peroxides were significantly higher in patients with PCa with respect to BPH. A positive correlation was found between peroxides and TEAC values in samples withdrawn locally in patients affected by PCa. An inverse correlation between peroxides and TEAC was observed in patients with BPH. No statistically significant modifications were observed as concerns SOD activity and LDL oxidability. Conclusions: Our findings confirm a significant unbalance of redox status in patients affected by BPH and PCa, and suggest a potential involvement of oxidative stress as a determinant in the pathogenesis of these diseases.
© 2010 S. Karger AG, Basel
Related Articles:
References
- Berry SJ, Coffey DS, Walsh PC, Ewing LJ: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.
- Boyle P, Ferlay J: Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481–485.
- Rohrmann S, Roberts WW, Walsh PC, Platz EA: Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate 2003;55:140–146.
- Heidenreich A, Aus G, Bolla M, et al: EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.
- Hammarsten J, Högstedt B: Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151–158.
- Hammarsten J, Högstedt B: Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high stage and high grade clinical prostate cancer. Blood Press 2004;13:47–55.
- Valko M, Rhodes CJ, Moncol J, et al: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1–40.
- Berger AP, Deibl M, Halpern EJ: Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia 2005;48:784–789.
- Ghafar MA, Puchner PJ, Anastasiadis AG, et al: Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002;3:292–296.
- Nandeesha H: Benign prostatic hyperplasia: dietary and metabolic risk factors. Int Urol Nephrol 2008;40:649–656.
- Di Massimo C, Scarpelli P, di Lorenzo N, et al: Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci 2006;78:1163–1167.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) final report. Circulation 2002;106:3143–3421.
- Miller NJ, Rice-Evans C, Davies MJ: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407–421.
- Di Massimo C, Taglieri G, Penco M, Tozzi-Ciancarelli MG: Influence of aging and excise on platelet function. Clin Hemorheol Microcirc 1999;20:105–110.
- Kumar B, Koul S, Khandrika L, et al: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777–1785.
- Aydin A, Arsova-Sarafinovska Z, Sayal A, et al: Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 2006;39:176–189.
- Tam NN, Nyska A, Maronpot RR, et al: Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants. Prostate 2006;66:57–69.
- Yamasaki M, Nomura T, Sato F, Mimata H: Metallothionein is upregulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 2007;18:1145–1153.
- Dogru-Abbasoglu S, Aykaç-Toker G, Koçak T, et al: Antioxidant enzymes activities and lipid peroxides in the plasma of patients with benign prostatic hyperplasia or prostate cancer are not predictive. J Cancer Res Clin Oncol 1999;125:402–404.
- Bostwick DG, Alexander EE, Singh R, et al: Antioxidant enzymes expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000;89:123–134.
- Sikka SC: Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention – a mechanistic approach. Curr Med Chem 2003;10:2679–2692.
- Lim SD, Sun C, Lambeth JD, et al: Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 2005;62:200–207.
- Pennathur S, Heinecke J: Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 2007;7:257–264.
-
Endemann DH, Schiffrin EL: Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep 2006;6:85–89.
External Resources
- Brook RD: Obesity, weight loss, and vascular function. Endocrine 2006;29:21–25.
- De Marzo AM, Platz EA, Sutcliffe S, et al: Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256–269.
- Olinski R, Zastawny TH, Foksinski M, et al: DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radic Biol Med 1995;18:807–813.
- Jung K, Seidel B, Rudolph B, et al: Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. Free Radic Biol Med 1997;23:127–133.
- Baker AM, Oberley LW, Cohen MB: Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 1997;32:229–233.
-
Gate L, Paul J, Nguyen Ba G, et al: Oxidative stress induced in pathologies: the role of antioxidant. Biomed Pharmacother 1990;53:169–180.
External Resources
Article / Publication Details
Received: November 26, 2009
Accepted: March 22, 2010
Published online: May 20, 2010
Issue release date: October 2010
Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 2
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
